Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
2.
Eur J Haematol ; 110(4): 371-378, 2023 Apr.
Article in English | MEDLINE | ID: mdl-36478591

ABSTRACT

In chronic lymphocytic leukemia (CLL), the immune system is skewed towards a suppressive milieu. Levels of thrombopoietin (TPO), promoting cellular immune regulatory activity in immune thrombocytopenic purpura, were shown to be elevated in CLL patients. This study explored TPO as a potential immunomodulator, supporting CLL progression. We evaluated CLL cell-induced expression of TPO receptor (TPO-R) on T-cells and effects of its activation on T-cell responses. CLL cell involvement in TPO generation was also assessed. Baseline TPO-R expression on CD4 + T-cells was found to be higher in CLL patients than in healthy controls (HC). Exposure of HC-T-cells to B-cells, especially to CLL-B-cells stimulated with B-cell activating molecules, resulted in enhanced TPO-R expression on T-cells. CLL-T-cell stimulation with TPO reduced their proliferation and expanded the regulatory T-cell (Treg) population. At baseline, phosphorylation of STAT5, known to impact the Treg phenotype, was elevated in CLL-T-cells relative to those of HC. Exposure to TPO further enhanced STAT5 phosphorylation in CLL-T-cells, possibly driving the observed Treg expansion. The CLL immune milieu is involved in promotion of inhibitory features in T-cells through increased TPO-R levels and TPO-induced intracellular signaling. TPO and its signaling pathway could potentially support immunosuppression in CLL, and may emerge as novel therapeutic targets.


Subject(s)
Leukemia, Lymphocytic, Chronic, B-Cell , Humans , Receptors, Thrombopoietin/metabolism , STAT5 Transcription Factor/metabolism , T-Lymphocytes, Regulatory , Immunosuppression Therapy , Thrombopoietin/metabolism
3.
Angiogenesis ; 22(1): 185-196, 2019 02.
Article in English | MEDLINE | ID: mdl-30386953

ABSTRACT

Bone marrow microenvironment is known to support angiogenesis, thus contributing to progression of multiple myeloma (MM). Bortezomib, a proteasome inhibitor (PI) widely used in MM treatment, has anti-angiogenic activity. Extracellular vesicles (EVs), shedding from cell surface, serve as mediators in cell-to-cell communication. We have hypothesized that MM cells (MMCs) treated with bortezomib generate EVs that could diminish angiogenesis, thus limiting MM progression. In the present study, EVs were obtained from MMCs (RPMI-8226), untreated (naïve) or pre-treated with bortezomib. EVs were outlined using NanoSight, FACS, protein arrays and proteasome activity assays. The impact of MMC-EVs on endothelial cell (EC) functions was assessed, employing XTT assay, Boyden chamber and Western blot. A high apoptosis level (annexin V binding 70.25 ± 16.37%) was observed in MMCs following exposure to bortezomib. Compared to naïve EVs, a large proportion of bortezomib-induced EVs (Bi-EVs) were bigger in size (> 300 nm), with higher levels of annexin V binding (p = 0.0043).They also differed in content, presenting with increased levels of pro-inflammatory proteins, reduced levels of pro-angiogenic growth factors (VEGFA, PDGF-BB, angiogenin), and displayed lower proteasome activity. Naïve EVs were found to promote EC migration and proliferation via ERK1/2 and JNK1/2/3 phosphorylation, whereas Bi-EVs inhibited these functions. Moreover, Bi-EVs appeared to reduce EC proteasome activity. EVs released from apoptotic MMCs following treatment with bortezomib can promote angiogenesis suppression by decreasing proliferation and migration of EC. These activities are found to be mediated by specific signal transduction pathways.


Subject(s)
Extracellular Vesicles , Human Umbilical Vein Endothelial Cells/metabolism , Multiple Myeloma/metabolism , Neovascularization, Pathologic/drug therapy , Proteasome Inhibitors , Bortezomib/pharmacokinetics , Bortezomib/pharmacology , Cell Line, Tumor , Extracellular Vesicles/metabolism , Extracellular Vesicles/pathology , Extracellular Vesicles/transplantation , Human Umbilical Vein Endothelial Cells/pathology , Humans , Multiple Myeloma/pathology , Neovascularization, Pathologic/metabolism , Neovascularization, Pathologic/pathology , Proteasome Inhibitors/pharmacokinetics , Proteasome Inhibitors/pharmacology
4.
Cancer Immunol Immunother ; 67(5): 739-748, 2018 May.
Article in English | MEDLINE | ID: mdl-29450641

ABSTRACT

Circulating chronic lymphocytic leukemia (CLL) cells share phenotypic features with certain subsets of regulatory B-cells (Bregs). The latter cells have been reported to negatively regulate immune cell responses, mostly by provision of IL-10. The purpose of the current study was to identify and delineate Breg properties of CLL cells. B-cells and T-cells were obtained from the peripheral blood of untreated CLL patients diagnosed according to the 2008 Guidelines of the International Workshop on Chronic Lymphocytic Leukemia. Co-culture assays were used to examine the ability of CLL cells to suppress autologous T-cell immune responses. IL-10 potency of CLL cells was assessed following stimulation with activators of the toll-like receptor 9 (TLR9) or CD40 and was correlated with the inhibitory activity of the cells. TLR9-activated CLL cells were found to increase the frequency of CD4+CD25hiFOXp3+ regulatory T-cells (Tregs) and to inhibit autologous CD4+ T-cell proliferation. This signaling cascade proved to control IL-10 generation in CLL cells, which in turn promoted the inhibition of T-cell proliferation by CLL cells. However, CD40 activation of CLL cells, while exhibiting a similar ability to augment Treg frequency, did not either affect IL-10 generation or T-cell proliferation. In conclusion, CLL cells demonstrate a unique clonal quality of adopting Breg properties which promote modulation of T-cell characteristics. TLR9 appears to be a potent activator of regulatory abilities in CLL cells, possibly contributing to preferential immune escape of TLR9-responsive cells.


Subject(s)
B-Lymphocytes, Regulatory/immunology , CD40 Antigens/immunology , Leukemia, Lymphocytic, Chronic, B-Cell/immunology , Lymphocyte Activation/immunology , T-Lymphocytes, Regulatory/immunology , Toll-Like Receptor 9/immunology , Adult , Aged , Aged, 80 and over , Cell Proliferation , Cells, Cultured , Female , Follow-Up Studies , Humans , Interleukin-10/metabolism , Male , Middle Aged , Prognosis , Signal Transduction
5.
Ann Hematol ; 96(3): 461-467, 2017 Mar.
Article in English | MEDLINE | ID: mdl-28013359

ABSTRACT

Bortezomib-based induction followed by autologous stem cell transplantation is a common treatment for multiple myeloma (MM). Stem cell (SC) mobilization with granulocyte-colony stimulating factor (G-CSF) alone has become an alternative to G-CSF combined with chemotherapeutic agents. This study aimed to compare the efficacy of the two mobilization modalities following induction with a uniform regimen containing bortezomib, cyclophosphamide and dexamethasone (VCD). We retrospectively evaluated results of SC mobilization using either G-CSF alone or combined with high-dose cyclophosphamide (HD-CY) in MM patients after VCD induction. The primary endpoints of the study were engraftment and mobilization-associated toxicity. Parameters of stem cell collection, transplantation and engraftment were assessed. Data of 92 patients were analyzed [56 (61%) mobilized with HD-CY + G-CSF and 36 (39%) with G-CSF only]. HD-CY + G-CSF provided a higher number of CD34 + cells (15.9 vs 8.1 × 106/kg, p = 0.001) with fewer apheresis sessions. However, while no adverse events were observed in patients receiving G-CSF alone, nine patients (16%) receiving HD-CY + G-CSF developed neutropenic fever requiring hospitalization. Although a greater number of cells was transplanted following mobilization with HD-CY + G-CSF, neutrophil and platelet engraftment and duration of transplant-related hospitalization were similar in both cohorts. G-CSF alone provided a sufficient SC amount, without exposing patients to additional toxicity. While HD-CY + G-CSF resulted in a superior SC yield in MM patients induced with VCD, this advantage should be balanced against adverse effects of this mobilization regimen.


Subject(s)
Bortezomib/administration & dosage , Cyclophosphamide/administration & dosage , Dexamethasone/administration & dosage , Hematopoietic Stem Cell Mobilization/methods , Multiple Myeloma/therapy , Transplantation Conditioning/methods , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Cohort Studies , Female , Humans , Male , Middle Aged , Multiple Myeloma/diagnosis , Retrospective Studies , Treatment Outcome
6.
Clin Cancer Res ; 19(13): 3640-8, 2013 Jul 01.
Article in English | MEDLINE | ID: mdl-23685836

ABSTRACT

PURPOSE: A multiple myeloma vaccine has been developed whereby patient-derived tumor cells are fused with autologous dendritic cells, creating a hybridoma that stimulates a broad antitumor response. We report on the results of a phase II trial in which patients underwent vaccination following autologous stem cell transplantation (ASCT) to target minimal residual disease. EXPERIMENTAL DESIGN: Twenty-four patients received serial vaccinations with dendritic cell/myeloma fusion cells following posttransplant hematopoietic recovery. A second cohort of 12 patients received a pretransplant vaccine followed by posttransplant vaccinations. Dendritic cells generated from adherent mononuclear cells cultured with granulocyte macrophage colony-stimulating factor, interleukin-4, and TNF-α were fused with autologous bone marrow-derived myeloma fusion cells using polyethylene glycol. Fusion cells were quantified by determining the percentage of cells that coexpress dendritic cell and myeloma fusion antigens. RESULTS: The posttransplant period was associated with reduction in general measures of cellular immunity; however, an increase in CD4 and CD8(+) myeloma-specific T cells was observed after ASCT that was significantly expanded following posttransplant vaccination. Seventy-eight percent of patients achieved a best response of complete response (CR)+very good partial response (VGPR) and 47% achieved a CR/near CR (nCR). Remarkably, 24% of patients who achieved a partial response following transplant were converted to CR/nCR after vaccination and at more than 3 months posttransplant, consistent with a vaccine-mediated effect on residual disease. CONCLUSIONS: The posttransplant period for patients with multiple myeloma provides a unique platform for cellular immunotherapy in which vaccination with dendritic cell/myeloma fusion fusions resulted in the marked expansion of myeloma-specific T cells and cytoreduction of minimal residual disease.


Subject(s)
Cancer Vaccines/immunology , Dendritic Cells/immunology , Hematopoietic Stem Cell Transplantation , Multiple Myeloma/immunology , Multiple Myeloma/therapy , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cancer Vaccines/administration & dosage , Cancer Vaccines/adverse effects , Female , Humans , Immunity, Cellular , Immunotherapy , Male , Middle Aged , Remission Induction , Transplantation, Autologous , Treatment Outcome , Vaccination
7.
Proc Natl Acad Sci U S A ; 107(44): 18769-76, 2010 Nov 02.
Article in English | MEDLINE | ID: mdl-20974924

ABSTRACT

The HLA molecules are membrane-bound transporters that carry peptides from the cytoplasm to the cell surface for surveillance by circulating T lymphocytes. Although low levels of soluble HLA molecules (sHLA) are normally released into the blood, many types of tumor cells release larger amounts of these sHLA molecules, presumably to counter immune surveillance by T cells. Here we demonstrate that these sHLA molecules are still bound with their authentic peptide repertoires, similar to those of the membranal HLA molecules (mHLA). Therefore, a single immunoaffinity purification of the plasma sHLA molecules, starting with a few milliliters of patients' blood, allows for identification of very large sHLA peptidomes by mass spectrometry, forming a foundation for development of a simple and universal blood-based cancer diagnosis. The new methodology was validated using plasma and tumor cells of multiple-myeloma and leukemia patients, plasma of healthy controls, and with cultured cancer cells. The analyses identified thousands of sHLA peptides, including some cancer-related peptides, present among the sHLA peptidomes of the cancer patients. Furthermore, because the HLA peptides are the degradation products of the cellular proteins, this sHLA peptidomics approach opens the way for investigation of the patterns of protein synthesis and degradation within the tumor cells.


Subject(s)
Antigens, Neoplasm , Biomarkers, Tumor , Neoplasms , Peptides , Proteome , Animals , Antigens, Neoplasm/blood , Antigens, Neoplasm/immunology , Biomarkers, Tumor/blood , Biomarkers, Tumor/immunology , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/metabolism , Histocompatibility Antigens Class I/immunology , Histocompatibility Antigens Class I/metabolism , Humans , Neoplasms/blood , Neoplasms/diagnosis , Neoplasms/immunology , Peptides/blood , Peptides/immunology , Proteome/immunology , Proteome/metabolism
8.
Infect Control Hosp Epidemiol ; 28(6): 755-7, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17520558

ABSTRACT

A gram-positive rod with a restriction pattern closely related to the published nucleotide sequence of Mycobacterium mucogenicum was isolated from 6 of 45 units of peripheral blood stem cell products. The source of the contamination was traced to ice cubes used in processing the peripheral blood stem cell products. Substituting reusable ice trays for ice from an ice machine terminated the outbreak.


Subject(s)
Equipment Contamination , Hematopoietic Stem Cells/microbiology , Ice/adverse effects , Mycobacterium Infections/microbiology , Mycobacterium/isolation & purification , Anti-Bacterial Agents/therapeutic use , Bone Marrow Transplantation , Disease Outbreaks/prevention & control , Humans , Infection Control/methods , Mycobacterium Infections/drug therapy , Polymerase Chain Reaction
9.
Biol Blood Marrow Transplant ; 13(3): 329-38, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17317586

ABSTRACT

In an attempt to abrogate the deleterious effects of graft-versus-host disease (GVHD), allogeneic transplantation for nonmalignant diseases was performed using high-dose CD34-cell infusion, partial T cell depletion, and no posttransplantation GVHD prophylaxis. Between 1998 and 2004, 16 patients with matched related donors were treated. Median age was 1.5 years (range, 5 months-18 years). The conditioning regimen consisted of busulphan 16 mg/kg, cyclophosphamide 200 mg/kg, antithymocyte globulin (ATG) 25 mg/kg, and fludarabine 200 mg/m(2). No GVHD prophylaxis was given. High doses of CD34 cells, positively selected by immunomagnetic beads, were infused at a median dose of 10.7 x 10(6) CD34/kg (range, 7.4-50 x 10(6)). A total of 1 x 10(5)/kg T cells were given. All patients engrafted, with no graft rejections. All were alive and well at a median of 37 months posttransplantation (range, 18-89 months). Only 1 patient developed chronic GVHD. No episodes of severe infection occurred during or after transplantation. Immunologic reconstitution with CD3/CD4 T cells > 200/microL was observed at a median of 117 days and that with naive T cells (CD4/CD45RA) at a median of 188 days posttransplantation. Our findings suggest that allogeneic transplantation from a matched family donor for nonmalignant disorders can be successfully performed using high doses of CD34 cells, moderate T cell depletion, and no posttransplantation immunosuppression.


Subject(s)
Bone Marrow Transplantation/methods , Graft vs Host Disease/prevention & control , Lymphocyte Depletion/methods , Adolescent , Antigens, CD34 , Child , Child, Preschool , Female , Graft Survival , Humans , Immune System/cytology , Infant , Male , Retrospective Studies , Survival Rate , Transplantation Conditioning/methods , Transplantation, Homologous , Treatment Outcome
10.
Br J Haematol ; 120(2): 329-36, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12542495

ABSTRACT

Hematopoietic reconstitution could be associated with premature ageing of the transplanted cells and a high frequency of myelodysplastic syndrome and secondary leukaemia. Telomere length decreases with cell divisions and age, and at a crucial length it is associated with chromosomal instability and cell senescence. Telomerase is a reverse transcriptase enzyme that adds nucleotides to chromosomal ends. Most somatic cells lack telomerase activity yet haematopoietic stem cells retain low levels of telomerase. Some studies have found that chemotherapy and stem cell transplantation lead to the accelerated shortening of telomere length. As granulocyte colony-stimulating factor (G-CSF) is routinely used in the mobilization of stem cells for transplantation, we evaluated its effects on telomerase activity and regulation, and on telomere dynamics, in normal donors and selected lymphoma patients. Administration of G-CSF increased telomerase activity in CD34+ haematopoietic cells compared with controls. In marrow-derived CD34+ cells, telomerase activity increased sevenfold, compared with a 14-fold increase in peripheral-blood-mobilized CD34+ cells. A parallel increase in the expression of human telomerase enzyme reverse transcriptase RNA and protein kinase C alpha occurred. In addition, G-CSF administration to five lymphoma patients after consecutive courses of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy, resulted in telomere length preservation or elongation, as opposed to marked attrition in patients who did not receive growth factors. We conclude that the in vivo administration of G-CSF prevents or attenuates telomere attrition associated with chemotherapy administration. This attenuation may contribute to the preservation of telomere integrity inG-CSF-primed transplanted stem cells.


Subject(s)
Antigens, CD34 , Granulocyte Colony-Stimulating Factor/pharmacology , Hematopoietic Stem Cell Mobilization , Hematopoietic Stem Cells/enzymology , Lymphoma/enzymology , Telomerase/metabolism , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Marrow Cells/drug effects , Bone Marrow Cells/enzymology , Cyclophosphamide/administration & dosage , Doxorubicin/administration & dosage , Enzyme Activation , Hematopoietic Stem Cells/drug effects , Hematopoietic Stem Cells/immunology , Humans , Lymphoma/drug therapy , Lymphoma/immunology , Middle Aged , Prednisone/administration & dosage , Protein Kinase C/genetics , Protein Kinase C-alpha , RNA/analysis , Telomerase/genetics , Telomere/genetics , Telomere/ultrastructure , Vincristine/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...